Advanced Breast Cancer: Expert Perspectives On Recent Progress

home / peer-exchange / advanced-breast-cancer-expert-perspectives-on-recent-progress
Perspectives on Recent Progress: Program Overview

EP. 1: Perspectives on Recent Progress: Program Overview

July 14th 2020
Phase 3 KEYNOTE-355 Overview

EP. 2: Phase 3 KEYNOTE-355 Overview

July 14th 2020
PD-L1 Testing Standard of Practice

EP. 3: PD-L1 Testing Standard of Practice

July 14th 2020
KEYNOTE-355 Regimen’s Role in Treatment Paradigm

EP. 4: KEYNOTE-355 Regimen’s Role in Treatment Paradigm

July 14th 2020
ASCO New Data: PARP Inhibitors

EP. 5: ASCO New Data: PARP Inhibitors

July 14th 2020
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews

EP. 6: SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews

July 14th 2020
Phase 3 ASCENT Regimen Accelerated Approval

EP. 7: Phase 3 ASCENT Regimen Accelerated Approval

July 14th 2020
Next-Generation Sequencing: Triple Negative Breast Cancer

EP. 8: Next-Generation Sequencing: Triple Negative Breast Cancer

July 14th 2020
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer

EP. 9: CDK4/6 Inhibition in HR+ Metastatic Breast Cancer

July 14th 2020
CDK4/6 Clinical Trial Survival Data Impact

EP. 10: CDK4/6 Clinical Trial Survival Data Impact

July 14th 2020
CDK4/6 Meta-Analysis Data

EP. 11: CDK4/6 Meta-Analysis Data

July 14th 2020
Mechanisms of Resistance to CDK4/6 Inhibitors

EP. 12: Mechanisms of Resistance to CDK4/6 Inhibitors

July 14th 2020
Significance of PIK3CA Mutation in HR+ Breast Cancer

EP. 13: Significance of PIK3CA Mutation in HR+ Breast Cancer

July 14th 2020
After Progression on PIK3CAi Therapy: MTOR Inhibition

EP. 14: After Progression on PIK3CAi Therapy: MTOR Inhibition

July 14th 2020
HER2+ MBC Adverse-Event Management

EP. 15: HER2+ MBC Adverse-Event Management

July 14th 2020
Notable ASCO Trial Updates

EP. 16: Notable ASCO Trial Updates

July 14th 2020